Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Winrevair slashes early PAH worsening by 76% in phase 3 Hyperion, but can it reset first-year care?
Winrevair reduced PAH clinical worsening by 76% in phase 3 Hyperion. Learn how Merck’s results could reset first-year treatment guidelines today.
Roche’s sixth-gen Troponin T test: Can it finally solve the accuracy problem in heart attack diagnosis?
Roche’s sixth-generation Troponin T test delivers new accuracy in heart attack diagnosis. Explore clinical results, adoption hurdles, and investor sentiment.
H2 Global Group enters growth phase with hydrogen therapy for Alzheimer’s and neurodegenerative diseases
H2 Global Group eyes EU and FDA milestones as it advances hydrogen therapy for Alzheimer’s and projects $48M revenues by 2029—read the in-depth analysis.
Genmab’s $8bn takeover of Merus: What it means for biotech M&A and the race to control antibody innovation
Find out how Genmab’s $8B acquisition of Merus and its petosemtamab asset is reshaping the oncology biotech race and investor sentiment today.
Lumonus signs multi-year licensing deal with Smarter Radiation Oncology to expand AI-powered cancer treatment standards
Lumonus partners with Smarter Radiation Oncology to embed evidence-based cancer treatment standards into its AI platform. Find out how this shapes oncology.
Paradigm Biopharmaceuticals (ASX: PAR) hits key Phase 3 milestone as dosing begins in U.S. and Australia
Paradigm Biopharmaceuticals (ASX: PAR) begins dosing in its pivotal Phase 3 osteoarthritis trial, setting up a mid-2026 data readout that could redefine its future.
Liquid biopsy breakthrough: FDA okays Guardant360 CDx to match patients to Eli Lilly’s Inluriyo
FDA approves Guardant360 CDx as a companion diagnostic for Inluriyo in ESR1-mutated breast cancer. Discover how liquid biopsy is reshaping oncology care today.
AbbVie’s bold gamble: Can Elahere really launch in the UK at full U.S. list price?
AbbVie plans to launch ovarian cancer drug Elahere in UK at U.S. price—testing NICE, NHS, and investor confidence in oncology pricing norms.
From Phase 3 data to Wall Street panic: Why MoonLake Immunotherapeutics lost 89% overnight
MoonLake’s VELA Phase 3 update rattled investors as MLTX crashed about 89%. Find out what the data really says and how week-52 could change the outlook.
Novo Nordisk seeks FDA nod for Mim8 — how will this impact hemophilia treatment and NVO stock?
Novo Nordisk files FDA application for Mim8 in hemophilia A. Learn how flexible dosing and trial data could redefine the bleeding disorder market.